1. Scrip
  2. >>Focus On Asia
  3. >>Japan

AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray

Japan Venture Joins Others In Same Approach

 
• By Ian Haydock

Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.

Scientists
Japanese, Other Firms Join Coronavirus Fight • Source: Shutterstock

In another potential arrow in the growing pharma R&D quiver against the spreading coronavirus, AnGes Inc. is working with Osaka University on a potential prophylactic DNA vaccine against the new coronavirus, in an effort making use of the Japanese bioventure's plasmid DNA experience.

Such vaccines have the advantage of usually shorter production lead times versus standard attenuated vaccines and those using recombinant virus proteins, which in the case of the spreading SARS-CoV-2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.